Remarkably, both CDK7-selective inhibitors were more effective in decreasing HNSCC cell viability than the CDK4/6 inhibitor palbociclib (>10-fold higher IC50 values) (Fig. 3a, b). The gene discussed is CDK4; the disease is head and neck squamous cell carcinoma.